Short- and long-term outcomes of adult allogeneic hematopoietic stem cell transplant patients admitted to the intensive care unit in the peritransplant period

Leukemia and Lymphoma

Volumn 58, Issue 2, 2017, Pages 382-390

  Mayer, Sebastian ^a   Pastores, Stephen M ^a,b   Riedel, Elyn ^b   Maloy, Molly ^b   Jakubowski, Ann A ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Allogeneic; intensive care; mortality; prognostic factors; stem cell transplantation

Indexed keywords

BILIRUBIN; CREATININE; HYPERTENSIVE AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ARTIFICIAL VENTILATION; CAUSE OF DEATH; CONTROLLED STUDY; FEMALE; GRAFT RECIPIENT; GRAM NEGATIVE SEPSIS; HOSPITAL ADMISSION; HOSPITAL MORTALITY; HOSPITALIZATION; HUMAN; INFECTION; INTENSIVE CARE UNIT; KIDNEY FAILURE; LIVER FAILURE; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RELAPSE; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; SEPSIS; SHORT TERM SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INTENSIVE CARE; MIDDLE AGED; MORTALITY; PERIOPERATIVE PERIOD; PROCEDURES; STATISTICS AND NUMERICAL DATA; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

ADULT; AGED; CRITICAL CARE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT ADMISSION; PERIOPERATIVE PERIOD; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

EID: 84976307722     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428194.2016.1195499     Document Type: Article

References (37)

1. Armitage JO. Bone marrow transplantation. N Engl J Med. 1994;330:827–838.
2. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy:harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89:4531–4536.
3. Bertz H, Potthoff K, Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol. 2003;21:1480.
4. Soubani AO, Kseibi E, Bander JJ, et al. Outcome and prognostic factors of hematopoietic stem cell transplantation recipients admitted to a medical ICU. Chest. 2004;126:1604–1611.
5. Price KJ, Thall PF, Kish SK, et al. Prognostic indicators for blood and marrow transplant patients admitted to an intensive care unit. Am J Respir Crit Care Med. 1998;158:876–884.
6. Scales DC, Thiruchelvam D, Kiss A, et al. Intensive care outcomes in bone marrow transplant recipients:a population-based cohort analysis. Crit Care. 2008;12:R77.
7. Faber-Langendoen K, Caplan AL, McGlave PB. Survival of adult bone marrow transplant patients receiving mechanical ventilation:a case for restricted use. Bone Marrow Transplant. 1993;12:501–507.
8. Afessa B, Tefferi A, Dunn WF, et al. Intensive care unit support and acute physiology and chronic health evaluation III performance in hematopoietic stem cell transplant recipients. Crit Care Med. 2003;31:1715–1721.
9. Allareddy V, Roy A, Rampa S, et al. Outcomes of stem cell transplant patients with acute respiratory failure requiring mechanical ventilation in the United States. Bone Marrow Transplant. 2014;49:1278–1286.
10. Galindo-Becerra S, Labastida-Mercado N, Rosales-Padrón J, et al. Outcome of recipients of hematopoietic stem cell transplants who require intensive care unit support:a single institution experience. Acta Haematol. 2015;134:119–124.
11. Pène F, Aubron C, Azoulay E, et al. Outcome of critically ill allogeneic hematopoietic stem-cell transplantation recipients:a reappraisal of indications for organ failure supports. J Clin Oncol. 2006;24:643–649.
12. Neumann F, Lobitz O, Fenk R, et al. The sepsis-related organ failure assessment (SOFA) score is predictive for survival of patients admitted to the intensive care unit following allogeneic blood stem cell transplantation. Ann Hematol. 2008;87:299–304.
13. Gilli K, Remberger M, Hjelmqvist H, et al. Sequential organ failure assessment predicts the outcome of SCT recipients admitted to intensive care unit. Bone Marrow Transplant. 2010;45:682–688.
14. Mokart D, Granata A, Crocchiolo R, et al. Allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning regimen:outcomes of patients admitted to intensive care unit. J Crit Care. 2015;30:1107–1113.
15. Townsend WM, Holroyd A, Pearce R, et al. Improved intensive care unit survival for critically ill allogeneic haematopoietic stem cell transplant recipients following reduced intensity conditioning. Br J Haematol. 2013;161:578–586.
16. Kew AK, Couban S, Patrick W, et al. Outcome of hematopoietic stem cell transplant recipients admitted to the intensive care unit. Biol Blood Marrow Transplant. 2006;12:301–305.
17. Benz R, Schanz U, Maggiorini M, et al. Risk factors for ICU admission and ICU survival after allogeneic hematopoietic SCT. Bone Marrow Transplant. 2014;49:62–65.
18. Castella X, Artigas A, Bion J, et al. A comparison of severity of illness scoring systems for intensive care unit patients:results of a multicenter, multinational study. The European/North American severity study group. Crit Care Med. 1995;23:1327–1335.
19. Giralt S, Ballen K, Rizzo D, et al. Reduced–intensity conditioning regimen workshop:defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15:367.
20. Reisner Y, Kapoor N, Kirkpatrick D, et al. Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet. 1981;2:327–331.
21. Tamari R, Chung SS, Papadopoulos EB, et al. CD34-selected hematopoietic stem cell transplants conditioned with myeloablative regimens and antithymocyte globulin for advanced myelodysplastic syndrome:limited graft-versus-host disease without increased relapse. Biol Blood Marrow Transplant. 2015;21:2106–2114.
22. Nash RA, Piñeiro LA, Storb R, et al. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. Blood. 1996;88:3634–3641.
23. Ponce DM, Sauter C, Devlin S, et al. A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantation. Biol Blood Marrow Transplant. 2013;19:799–803.
24. Cutler C, Kim HT, Hochberg E, et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2004;10:328–336.
25. Hosmer DW, Jr., Lemeshow S. Applied logistic regression, 2nd ed., New York:John Wiley & Sons. 2000.
26. Lin DY, Wei LJ, Ying Z. Checking the cox model with cumulative sums of martingale-based residuals. Biometrika. 1993;80:557–572.
27. Trinkaus MA, Lapinsky SE, Crump M, et al. Predictors of mortality in patients undergoing autologous hematopoietic cell transplantation admitted to the intensive care unit. Bone Marrow Transplant. 2009;43:411–415.
28. Kim SW, Kami M, Urahama N, et al. Feasibility of acute physiology and chronic health evaluation (APACHE) II and III score-based screening in patients receiving allogeneic hematopoietic stem-cell transplantation. Transplantation. 2003;75:566–570.
29. Jackson SR, Tweeddale MG, Barnett MJ, et al. Admission of bone marrow transplant recipients to the intensive care unit:outcome, survival and prognostic factors. Bone Marrow Transplant. 1998;21:697–704.
30. Torrecilla C, Cortes JL, Chamarro C, et al. Prognostic assessment of the acute complications of bone marrow transplantation requiring intensive therapy. Intensive Care Med. 1988;14:393–398.
31. Huynh TN, Weigt SS, Belperio JA, et al. Outcome and prognostic indicators of patients with hematopoietic stem cell transplants admitted to the intensive care unit. J Transplant. 2009;2009:917294.
32. Kersting S, Koomans HA, Hené RJ, et al. Acute renal failure after allogeneic myeloablative stem cell transplantation:retrospective analysis of incidence, risk factors and survival. Bone Marrow Transplant. 2007;39:359–365.
33. Sorror M, Storer B, Sandmaier BM, et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer. 2008;112:1992–2001.
34. Corradini P, Zallio F, Mariotti J, et al. Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies. J Clin Oncol. 2005;23:6690–6698.
35. Lengliné E, Chevret S, Moreau AS, et al. Changes in intensive care for allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2015;50:840.
36. Bokhari SW, Munir T, Memon S, et al. Impact of critical care reconfiguration and track-and-trigger outreach team intervention on outcomes of haematology patients requiring intensive care admission. Ann Hematol. 2010;89:505–512.
37. Jaffe D, Jakubowski A, Sepkowitz K, et al. Prevention of peritransplantation viridans streptococcal bacteremia with early vancomycin administration:a single-center observational cohort study. Clin Infect Dis. 2004;39:1625–1632.